Early-stage trial data on AstraZeneca coronavirus vaccine due Monday
Early-stage human trial data on a COVID-19 vaccine being developed by AstraZeneca and Oxford University will be published by July 20, the Lancet mediacal journal has said. The vaccine candidate is already in large-scale Phase III human trials to assess whether it can protect against COVID-19, but its developers have yet to report Phase I results which would show whether it is safe and whether or not it induces an immune response.
The statement by Lancet came after several reports said that that Phase I data could be released as soon as Thursday. Developers of the vaccine, known as known as AZD1222, said earlier this month they were encouraged by the immune response they had seen in trials so far and were expecting to publish Phase 1 data by the end of July. A preclinical trial of the shot in pigs showed that two doses produced a greater antibody response than a single dose.